methane and Diarrhea
methane has been researched along with Diarrhea in 17 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dietary fructans exacerbate symptoms in some, but not all, adults with irritable bowel syndrome (IBS)." | 9.27 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome. ( Ali, A; Chumpitazi, BP; Elsaadi, A; McMeans, AR; Orlando, S; Shulman, RJ; Vaughan, A, 2018) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 9.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "We aimed to study (1) if the breath methane level on glucose breath testing (GBT) was associated with constipation severity and (2) compare methane levels between patients with constipation and diarrhea." | 7.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 7.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 7.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| "Dietary fructans exacerbate symptoms in some, but not all, adults with irritable bowel syndrome (IBS)." | 5.27 | Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome. ( Ali, A; Chumpitazi, BP; Elsaadi, A; McMeans, AR; Orlando, S; Shulman, RJ; Vaughan, A, 2018) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 5.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "We aimed to study (1) if the breath methane level on glucose breath testing (GBT) was associated with constipation severity and (2) compare methane levels between patients with constipation and diarrhea." | 3.96 | Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation. ( Ballou, S; Duehren, S; Iturrino, J; Katon, J; Lembo, A; Nee, J; Patel, R; Rangan, V; Singh, P, 2020) |
| "Lactulose breath test graphs of 561 patients of all irritable bowel syndrome subtypes were grouped into categories based on their hydrogen + methane levels with respect to time." | 3.83 | Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome. ( Adler, M; Dhingra, S; Guttermuth, C; Kasir, R; Lee, A; Zakko, P; Zakko, S, 2016) |
| "Methane excretion is clearly associated with alterations in intestinal motility, particularly favouring those with constipation." | 3.78 | Reassessment of the role of methane production between irritable bowel syndrome and functional constipation. ( Bruzzone, L; Dulbecco, P; Furnari, M; Gemignani, L; Giannini, EG; Moscatelli, A; Savarino, E; Savarino, V; Zentilin, P, 2012) |
| "Methane-producing IBS patients have a unique cluster of symptoms related to constipation." | 3.77 | Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome. ( Low, K; Makhani, M; Mirocha, J; Pimentel, M; Yang, J, 2011) |
| "We have previously shown that methane on lactulose breath test (LBT) is highly associated with constipation in IBS and that methane gas itself slows small bowel transit in dogs." | 3.72 | IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. ( Kong, Y; Park, S; Pimentel, M, 2004) |
| "Lactose intolerance is caused by lactase enzyme deficiency in the small bowel mucosa leading to lactose malabsorption and symptoms of bloating, gas, and diarrhea." | 2.82 | Bacterial overgrowth and lactose intolerance: how to best assess. ( Ghafoor, A; Karunaratne, T; Rao, SSC, 2022) |
Research
Studies (17)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ghafoor, A | 1 |
| Karunaratne, T | 1 |
| Rao, SSC | 1 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Liu, T | 1 |
| Li, Y | 1 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 1 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 1 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 1 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 1 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Li, S | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Huang, L | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 2 |
| Niu, X | 1 |
| Liu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhang, Y | 1 |
| Li, J | 2 |
| Zhao, M | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 1 |
| Zhao, D | 1 |
| Zhang, L | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 1 |
| Luo, Y | 1 |
| Zheng, D | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Tansel, A | 1 |
| Levinthal, DJ | 1 |
| Chumpitazi, BP | 1 |
| McMeans, AR | 1 |
| Vaughan, A | 1 |
| Ali, A | 1 |
| Orlando, S | 1 |
| Elsaadi, A | 1 |
| Shulman, RJ | 1 |
| Singh, P | 1 |
| Duehren, S | 1 |
| Katon, J | 1 |
| Rangan, V | 1 |
| Ballou, S | 1 |
| Patel, R | 1 |
| Iturrino, J | 1 |
| Lembo, A | 1 |
| Nee, J | 1 |
| Ghoshal, UC | 2 |
| Srivastava, D | 2 |
| Ghoshal, U | 2 |
| Misra, A | 1 |
| Kasir, R | 1 |
| Zakko, S | 1 |
| Zakko, P | 1 |
| Adler, M | 1 |
| Lee, A | 1 |
| Dhingra, S | 1 |
| Guttermuth, C | 1 |
| Shukla, R | 1 |
| Makhani, M | 1 |
| Mirocha, J | 1 |
| Low, K | 1 |
| Pimentel, M | 2 |
| Furnari, M | 1 |
| Savarino, E | 1 |
| Bruzzone, L | 1 |
| Moscatelli, A | 1 |
| Gemignani, L | 1 |
| Giannini, EG | 1 |
| Zentilin, P | 1 |
| Dulbecco, P | 1 |
| Savarino, V | 1 |
| Holma, R | 1 |
| Korpela, R | 1 |
| Sairanen, U | 1 |
| Blom, M | 1 |
| Rautio, M | 1 |
| Poussa, T | 1 |
| Saxelin, M | 1 |
| Osterlund, P | 1 |
| Kong, Y | 1 |
| Park, S | 1 |
| Hallfrisch, J | 1 |
| Behall, KM | 1 |
| Ballard, CA | 1 |
| Qilligan, EJ | 1 |
| Yamagata, S | 1 |
| Ichikawa, M | 1 |
| Masamune, O | 1 |
| Mita, M | 1 |
| Takahashi, T | 1 |
| Karim, SM | 1 |
| Sharma, SD | 1 |
| Alustiza, F | 1 |
| Bellingeri, R | 1 |
| Picco, N | 1 |
| Motta, C | 1 |
| Grosso, MC | 1 |
| Barbero, CA | 1 |
| Acevedo, DF | 1 |
| Vivas, A | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intestinal Microbiome Fructan Metabolism and Symptom Generation in Childhood IBS[NCT02842281] | 55 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Change From Baseline in Breath Methane Production Based on a Single-point Breath Methane Test
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Change From Baseline in the Weekly Average Number of Completely Spontaneous Bowel Movements (CSBM) Compared to the 12-week Treatment Period
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Mean Change From Baseline in the Area-under-the-curve (AUC) of Breath Methane Production, Based on the 120-minute Lactulose Breath Test.
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
Proportion of Overall Abdominal Pain Intensity Responders During the 12-week Treatment Period
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
Proportion of Overall Bloating Responders During the 12-week Treatment Period
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
Proportion of Overall Responders During the 12-week Treatment Period
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
Proportion of Overall Stool Frequency Responders During the 12-week Treatment Period
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Proportion of Patients Using Rescue Medication
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Proportion of Patients With Adequate Relief
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
Reviews
3 reviews available for methane and Diarrhea
| Article | Year |
|---|---|
Bacterial overgrowth and lactose intolerance: how to best assess.
Topics: Breath Tests; Diarrhea; Humans; Hydrogen; Lactase; Lactose Intolerance; Methane | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth.
Topics: Breath Tests; Diarrhea; Humans; Hydrogen; Intestine, Small; Methane | 2023 |
Trials
6 trials available for methane and Diarrhea
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Fructans Exacerbate Symptoms in a Subset of Children With Irritable Bowel Syndrome.
Topics: Adolescent; Breath Tests; Child; Cross-Over Studies; Diarrhea; Dietary Supplements; Double-Blind Met | 2018 |
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.
Topics: Adolescent; Adult; Aged; Blind Loop Syndrome; Breath Tests; Diarrhea; Female; Glucose; Humans; Hydro | 2014 |
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj | 2013 |
Breath hydrogen and methane responses of men and women to breads made with white flour or whole wheat flours of different particle sizes.
Topics: Adult; Bread; Breath Tests; Diarrhea; Digestion; Female; Flatulence; Flour; Humans; Hydrogen; Male; | 1999 |
[Influences of methylscopolammonium methylsulfate upon function of the digestive tract].
Topics: Abdomen; Adult; Clinical Trials as Topic; Diarrhea; Digestive System; Duodenal Ulcer; Electromyograp | 1972 |
Other Studies
9 other studies available for methane and Diarrhea
| Article | Year |
|---|---|
Breath Methane Does Not Correlate With Constipation Severity or Bloating in Patients With Constipation.
Topics: Breath Tests; Constipation; Diarrhea; Humans; Irritable Bowel Syndrome; Methane | 2020 |
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Breath Tests; Constipation; Diarrhea; Fema | 2016 |
Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in
Topics: Adult; Aged; Area Under Curve; Breath Tests; Case-Control Studies; Constipation; Diarrhea; Feces; Fe | 2016 |
Factor analysis demonstrates a symptom cluster related to methane and non-methane production in irritable bowel syndrome.
Topics: Breath Tests; Constipation; Diarrhea; Factor Analysis, Statistical; Humans; Irritable Bowel Syndrome | 2011 |
Reassessment of the role of methane production between irritable bowel syndrome and functional constipation.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bacteria; Breath Tests; Constipation; Defec | 2012 |
IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen.
Topics: Adolescent; Adult; Aged; Breath Tests; Chromatography, High Pressure Liquid; Constipation; Diarrhea; | 2004 |
Midtrimester abortion with intramuscular injection of 15-methyl-prostaglandin E2.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Chlorpromazine; Diarrhea; Drug Evaluation; Esters; F | 1974 |
Termination of second trimester pregnancy with 15 methyl analogues of prostaglandins E 2 and F 2 .
Topics: Abortion, Therapeutic; Amnion; Diarrhea; Female; Gestational Age; Humans; Injections; Injections, In | 1972 |
IgY against enterotoxigenic Escherichia coli administered by hydrogel-carbon nanotubes composites to prevent neonatal diarrhoea in experimentally challenged piglets.
Topics: Animals; Diarrhea; Enterotoxigenic Escherichia coli; Escherichia coli Infections; Hydrogels; Immunog | 2016 |